Drug Health Care 2013: Hot Railroad Stocks To Own For 2014

Why are markets going to keep going up? �

Because as long as the easy money party being put on by the central banks globally lasts they have to.

At least that is what Jim Rogers thinks.

He also warns that at some point in time that party has to stop. �When it does it is going to get ugly.

One market Jim Rogers would favor is Japan, specifically its blue chip companies. �New taxation policies in Japan have made stocks very attractive for Japanese citizens.

If you are interested in investing for the long term you should consider investing where the Chinese government will be investing which is in railroads and other things that will address China's pollution.

About the author:Canadian Valuehttp://valueinvestorcanada.blogspot.com/
Currently 1.50/512345

Rating: 1.5/5 (2 votes)

Hot Small Cap Companies To Own In Right Now: UGI Corporation (UGI)

UGI Corporation distributes, stores, transports, and markets energy products and related services in the United States and internationally. It distributes propane to approximately 2.3 million residential, commercial/industrial, motor fuel, agricultural, and wholesale customers in 50 states through 2,100 propane distribution locations; and sells, installs, and services propane appliances, including heating systems. The company also distributes liquid petroleum gas (LPG) to residential, commercial, industrial, agricultural, and automobile fuel customers for space and water heating, cooking, process heat, forklifts, transportation, construction work, manufacturing, crop drying, power generation, and irrigation; and provides logistic and storage services to third-party LPG distributors. In addition, it distributes natural gas to approximately 600,000 customers primarily in the portions of 46 eastern and central Pennsylvania counties through its distribution system of 12,000 mi les of gas mains; and supplies electricity to approximately 60,000 customers in northeastern Pennsylvania through 2,100 miles of transmission and distribution lines, and 13 transmission substations. Further, the company is involved in the retail sale of natural gas, liquid fuels, and electricity to approximately 18,000 commercial and industrial customers at approximately 43,000 locations. Additionally, it operates electric generation facilities, which include solar and landfill gas facilities; a natural gas liquefaction, storage, and vaporization facility; propane storage and propane-air mixing stations; and rail transshipment terminals. The company also manages natural gas pipeline and storage contracts; and develops, owns, and operates pipelines, gathering infrastructure, and gas storage facilities. In addition, it provides heating, ventilation, air conditioning, refrigeration, and electrical contracting services. The company was founded in 1882 and is based in King of Pru ssia, Pennsylvania.

Advisors' Opinion:

[By Laura Brodbeck]
Monday
Earnings Releases Expected: UGI Corporation (NYSE: UGI), Yum! Brands, Inc. (NYSE: YUM), First Bancorp. (NYSE: FBP) Economic Releases Expected: �Indian services PMI, Spanish services PMI, Italian services PMI, German services PMI, eurozone services PMI, British services PMI, German CPI, US ISM non-manufacturing PMI
Tuesday
[By Laura Brodbeck]
Monday
Earnings Releases Expected: Tyson Foods, Inc. (NYSE: TSN), UGI Corporation (NYSE: UGI), Salesforce.com Inc (NYSE: CRM Economic Releases Expected: Hong Kong unemployment rate, eurozone current account, Spanish current account
Tuesday
[By Rich Smith]
AmeriGas Propane, the general partner of AmeriGas Partners (NYSE: APU ) and subsidiary of propane distributor UGI (NYSE: UGI ) , announced Monday that it has promoted its treasurer, Hugh J. Gallagher, to the position of company vice president for finance, and chief financial officer.

Hot Railroad Stocks To Own For 2014: WEX Inc (WEX)

WEX Inc., formerly Wright Express Corporation, incorporated on June 18, 1999, is a provider of corporate card payment solutions. The Company operates in two segments: Fleet Payment Solutions and Other Payment Solutions. The Fleet Payment Solutions segment provides customers with fleet vehicle payment processing services specifically designed for the needs of commercial and government fleets. The Other Payment Solutions segment provides customers with payment processing solutions for their corporate purchasing and transaction monitoring needs through the Company's payment products. The Company's United States operations include WEX Inc., and the Company's wholly owned subsidiaries Fleet One, WEX Bank, rapid! PayCard, and Pacific Pride. On October 4, 2012, the Company acquired Fleet One. On August 30, 2012, the Company acquired a 51 % controlling interest in UNIK S.A. On May 11, 2012, the Company acquired CorporatePay Limited.

The Company's virtual card is used for transactions where no card is presented, including, for example, transactions conducted over the telephone, by mail, by fax or on the Internet. The Company's virtual card also can be used for transactions that require pre-authorization, such as hotel reservations. The rapid! PayCard product, a pre-paid payroll card, provides a paycard benefit and ePayroll program designed for employers choosing to convert to electronic delivery of payroll in the United States, replacing paper employee payroll checks. The Company also has several other product offerings, including corporate purchase cards and pre-paid and gift cards.

Fleet Payment Solutions

The Company's closed-loop fuel networks afford the Company access to a higher level of fleet-specific information and control than is widely available on open-loop networks. This allows the Company to improve and refine the information reporting the Company provides to its fleet customers and strategic relationships. The Company offers a differentiated set of products ! and services, including security and purchases controls, to allow its customers and the customers of its strategic relationships to better manage their vehicle fleets. The Company provides customized analysis and reporting on the efficiency of fleet vehicles and the purchasing behavior of fleet vehicle drivers. The Company's software facilitates the collection of information and affords the Company a high level of control and flexibility in allowing fleets to restrict purchases and receive automated alerts.

Hot Railroad Stocks To Own For 2014: S&P 500/Barra Value(SU)

Suncor Energy Inc., together with its subsidiaries, operates as an integrated energy company. The company involves in the development of petroleum resource basins in Canada's Athabasca oil sands; acquisition, exploration, development, production, and marketing of crude oil and natural gas in Canada and internationally; transportation and refining of crude oil; and marketing of petroleum and petrochemical products primarily in Canada. Its Oil Sands segment produces bitumen recovered from oil sands through mining and in-situ technology, and upgrades it into refinery feedstock, diesel fuel, and by-products. This segment?s products include gasoline and distillates. The company?s Natural Gas segment acquires, explores, develops, and produces natural gas, natural gas liquids, oil, and by-products from reserves located primarily in western Canada, the Northwest Territories, Alaska, and the Arctic Islands. Its International and Offshore segment engages in the exploration and pro duction of oil and gas in offshore Newfoundland and Labrador, in the North Sea, and in Libya and Syria. The company?s Refining and Marketing segment refines crude oil at Suncor's refineries in Edmonton, Alberta; Montreal, Quebec; and Sarnia, Ontario in Canada, as well as in Commerce City, Colorado into a range of petroleum and petrochemical products for sale to retail, commercial, and industrial customers. It also transports crude oil through pipelines in eastern and western Canada, as well as through wholly-owned pipelines in Wyoming and Colorado; and produces specialty lubricants and waxes. In addition, this segment operates retail sites in Canada under the Petro-Canada brand; and in Colorado under Phillips 66 and Shell brands. Suncor Energy Inc. also engages in third-party energy trading activities. The company was formerly known as Suncor Inc. and changed its name to Suncor Energy Inc. in April 1997. Suncor Energy Inc. was founded in 1953 and is headquartered in Calgary , Canada.

Advisors' Opinion:

[By Arjun Sreekumar]
Given current oil prices, that means several projects are barely profitable, leading some oil sands operators to reconsider new ventures. For instance, Suncor Energy (NYSE: SU ) , one of the largest oil sands producers by output, has been mulling over the profitability of three mining-related ventures jointly proposed with French oil major Total (NYSE: TOT ) .

Hot Railroad Stocks To Own For 2014: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

[By Sean Williams]
The other factor that makes J&J a company I wouldn't dare bet against is its top-notch pharmaceutical program. J&J has delivered incredible wins over the past couple of quarters including the approval of Invokana, the first SGLT-2 inhibitor approved in the U.S. to treat Type 2 diabetes, as well as its December 2011 licensing partnership with Pharmacyclics (NASDAQ: PCYC ) over experimental drug, ibrutinib, which has been designated as a breakthrough therapy by the Food and Drug Administration for the treatment of two rare blood cancers and could generate up to $5 billion in peak sales if approved (it's currently under review by the FDA).
[By Mani]
Pharmacyclics, Inc. (NASDAQ: PCYC) is one of the best ways to play the hematology cancer drug market as its Ibrutinib is expected to transform the treatment of many blood cancers.
[By Sean Williams]
Biotechnology juggernaut Pharmacyclics (NASDAQ: PCYC ) -- a company that has returned close to 19,000% since its recession lows -- ignited investor optimism when it and licensing partner Johnson & Johnson (NYSE: JNJ ) filed a new drug application for ibrutinib. This is truly exciting news, because it marks the first breakthrough therapy drug that's filed for an NDA, and will act the test subject to the rest of the breakthrough therapy designated drugs. Ibrutinib delivered exceptional results in chronic lymphocytic leukemia and mantle cell lymphoma in terms of overall response rate, which should probably net it an approval from the Food and Drug Administration.
[By Maxx Chatsko]
The astounding rise of Pharmacyclics (NASDAQ: PCYC ) through the markets has been largely based on its BTK inhibitor ibrutinib, which is being evaluated in four types of blood cancers and in a preclinical study for autoimmune indications. The rise is no fluke, either. Ibrutinib has shown very promising results in two phase 2 trials as a monotherapy and will soon be moved to phase 3 trials for both. With billions of dollars between the lymphoma and autoimmune markets up for grabs, it is easy to see why shares have risen 2,000% since the company acquired its lead drug candidate in 2006. Can Celgene tap into this multibillion opportunity with CC-292? Ask me again in about five years.�

Hot Railroad Stocks To Own For 2014: Noranda Aluminum Holding Corporation (NOR)

Noranda Aluminum Holding Corporation engages in the production and sale of primary aluminum products and rolled aluminum coils in the United States. Its Bauxite segment mines, produces, and sells bauxite used for alumina production. The company�s Alumina segment refines and converts bauxite into alumina, which is used in the production of primary aluminum; and sells smelter grade alumina and alumina hydrate, or chemical-grade alumina. Noranda Aluminum Holding Corporation�s Primary Aluminum segment produces and sells aluminum products in various forms, including billets, rods, high purity sow and foundry, and commodity grade sow. The company�s Flat-Rolled Products segment produces rolled aluminum products, such as finstock for use in commercial, residential, and automotive applications; semi-rigid containers for pre-packaged foods; flexible packaging products for food, drink, agricultural, and industrial products; and transformer windings for use on power grids. This seg ment sells its products through sales force to original equipment manufacturers of air conditioners, transformers, semi-rigid containers, and foil packaging; and other metals end-users. The company was incorporated in 2007 and is headquartered in Franklin, Tennessee.

Advisors' Opinion:

[By Pendulum]
Century Aluminum's stock price has held up well compared to other aluminum companies:
AlcoaNoranda Aluminum (NOR)Aluminum Corp. of China (ACH)
[By Garrett Cook]
In trading on Wednesday, basic materials shares were relative leaders, up on the day by about 0.87 percent. Meanwhile, top gainers in the sector included Noranda Aluminum Holding (NYSE: NOR), up 4.6 percent, and Cliffs Natural Resources (NYSE: CLF), up 3.4 percent.

Hot Railroad Stocks To Own For 2014: DRDGOLD Ltd (DRD)

DRDGOLD Limited (DRDGOLD), incorporated on February 16, 1895, is a South Africa-based surface gold retreatment company. DRDGOLD operates in a single segment, Ergo. Ergo is a surface retreatment operation and treats old slime and sand dumps to the south of Johannesburg�� central business district, as well as the east and central Rand goldfields. The operation consists of four plants: Brakpan, Crown, City and Knights. Included in the Ergo segment is the East Rand Proprietary Mines Limited (ERPM) surface operation comprise the Cason retreatment operation. Ergo is evaluating the viability of processing surface uranium- and sulphur-bearing tailings on the east and central Rand goldfields of South Africa. The Company�� business includes Crown Gold Recoveries (Pty) Limited (Crown), Ergo Mining (Pty) Limited (Ergo JV) and ErgoGold are jointly referred to as ERGO and ERPM. On June 1, 2012, the Company disposed of its 74% interest in and loan claims against Blyvoor.

The Company�� focus is on the recovery of lower-risk, lower-cost, higher-margin ounces. As of October 9, 2012, 68% of production comes from surface retreatment operation. The company holds a 74%-interest in operating subsidiary Ergo Mining Operations (Proprietary) Limited. Crown is the gold surface tailings retreatment facility, reprocessing the large and numerous sand and slimes dumps along the reefs that stretch from east to west just to the south of Johannesburg�� central business district (CBD). Crown�� major project is Top Star, a tailings dam to the south of Johannesburg�� CBD. ERPM is situated on the Witwatersrand Basin near the town of Boksburg, 25 kilometers to the east of Johannesburg. The Ergo as a joint venture between DRDGOLD and Mintails Limited. Wholly owned by the DRDGOLD group, Ergo has a network of surface rights that provide access to a further 600 million tons of surface tailings deposited across the western, central and eastern Witwatesrand. Ergo has three tailings deposition facilities. ERPM continues ! as a surface retreatment operation. It holds 65% of ErgoGold through the contribution of its Elsburg Tailings Complex.

Advisors' Opinion:

[By Roland Head]
DRDGold (NYSE: DRD ) climbed 4.2% to $6.25 last week. Rather than mining gold, this South African firm is focused on large-scale reprocessing of the tailings, or waste piles, of large gold mines in order to extract the gold that was not captured by the original mining process. This business is heavily mechanized and requires a relatively small workforce, giving DRDGold some protection from the rising labor costs that are reducing the profitability of many South African mining firms.
[By Garrett Cook]
Basic materials shares gained 0.10 percent in trading on Friday. Meanwhile, top gainers in the sector included DRDGOLD (NYSE: DRD), up 8.2 percent, and LyondellBasell Industries NV (NYSE: LYB), up 4.79 percent.

Drug Health Care 2013

Sunday, September 21, 2014

Hot Railroad Stocks To Own For 2014

Hot Small Cap Companies To Own In Right Now: UGI Corporation (UGI)

Hot Railroad Stocks To Own For 2014: WEX Inc (WEX)

Hot Railroad Stocks To Own For 2014: S&P 500/Barra Value(SU)

Hot Railroad Stocks To Own For 2014: Pharmacyclics Inc (PCYC)

Hot Railroad Stocks To Own For 2014: Noranda Aluminum Holding Corporation (NOR)

Hot Railroad Stocks To Own For 2014: DRDGOLD Ltd (DRD)

No comments:

Post a Comment